Treatments for Brain Metastases With Poor Prognostic Factors
TBMPPF
Effects of Local and Systemic Treatments in Brain Metastases With Poor Prognostic Factors: Multicenter Retrospective Study
1 other identifier
observational
2,000
1 country
1
Brief Summary
The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are:
- What kind of local treatment provides a survival benefit for patients with poor prognostic factors?
- What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors?
- Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors? Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 2, 2022
CompletedFirst Posted
Study publicly available on registry
November 8, 2022
CompletedStudy Start
First participant enrolled
December 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 20, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 20, 2024
CompletedDecember 15, 2022
December 1, 2022
11 months
November 2, 2022
December 13, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
OS
Overall survival time
From date of first follow-up until the date of documented death from any cause, assessed up to 120 months
Secondary Outcomes (1)
PFS
From date of first follow-up until the date of first documented progression, assessed up to 120 months
Study Arms (6)
local treatment group vs non-local treatment group
Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group or otherwise into non-local treatment group
systemic treatment group vs non-systemic treatment group
Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group or otherwise into non-systemic treatment group
local treatment group vs systemic treatment group
Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group
local treatment group vs local treatment+systemic treatment group
Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
systemic treatment group vs local treatment+systemic treatment group
Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group
local treatment+systemic treatment group vs non-local treatment+systemic treatment group
Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group or otherwise into non-local treatment+systemic treatment group
Interventions
neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide
Eligibility Criteria
Hospital clients from Sun Yat-sen University Cancer Center, Guangxi Medical University Cancer Hospital, The People's Hospital Of Guangxi Zhuang Autonomous Region, and the First Affiliated Hospital of Guangxi Medical University will be selected.
You may qualify if:
- Evidence of pathological diagnosis of primary tumor;
- Brain metastases confirmed by enhanced magnetic resonance imaging;
- Complete clinical information
You may not qualify if:
- Survival time less than 30 days;
- If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery;
- Incomplete clinical data;
- Patients with 2 or more types of tumors.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510006, China
Related Publications (1)
Li A, Feng D, Liu C, Huang C, Li T, Wei D, Wei F, Shen M, Qin C, Deng S, Liang H, Mo P, Dong M, Yu Y, Liang L. Prognostic Analysis of Lung Cancer With Brain Metastases in Elderly Patients: A Multicenter Retrospective Study. Aging Med (Milton). 2025 Dec 31;8(6):585-591. doi: 10.1002/agm2.70060. eCollection 2025 Dec.
PMID: 41531790DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Department of Neurosurgery
Study Record Dates
First Submitted
November 2, 2022
First Posted
November 8, 2022
Study Start
December 15, 2022
Primary Completion
November 20, 2023
Study Completion
November 20, 2024
Last Updated
December 15, 2022
Record last verified: 2022-12
Data Sharing
- IPD Sharing
- Will not share
We decided not to share the IPD because the study involved a lot of people's privacy